AZD-0424

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H29ClN6O5
Molecular Weight	528.988
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)OC1=CC(OCCN2CCN(CC2)C(C)=O)=CC3=C1C(NC4=C5OCOC5=NC=C4Cl)=NC=N3

InChI

InChIKey=MVWATCATLSSVBH-UHFFFAOYSA-N

InChI=1S/C25H29ClN6O5/c1-15(2)37-20-11-17(34-9-8-31-4-6-32(7-5-31)16(3)33)10-19-21(20)24(29-13-28-19)30-22-18(26)12-27-25-23(22)35-14-36-25/h10-13,15H,4-9,14H2,1-3H3,(H,27,28,29,30)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29438361 | https://clinicaltrials.gov/ct2/show/NCT01668550

AZD0424, a dual selective Src/Abl kinase inhibitor that has shown evidence of anti-tumor activity in pre-clinical studies. AZD0424 participated in phase I clinical trials in patients with advanced solid tumors, but this study was terminated because of insufficient evidence of efficacy as monotherapy.

Originator

Approval Year

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.

Route of Administration: Oral

Name

Type

Language

AZD-0424

Common Name

English

7-(2-(4-ACETYLPIPERAZIN-1-YL)ETHOXY)-4-(5-CHLORO-2,3-METHYLENEDIOXYPYRIDIN-4-YLAMINO)-5-ISOPROPOXYQUINAZOLINE

Systematic Name

English

AZD0424

Code

English

PIPERAZINE, 1-ACETYL-4-(2-((4-((6-CHLORO-1,3-DIOXOLO(4,5-B)PYRIDIN-7-YL)AMINO)-5-(1-METHYLETHOXY)-7-QUINAZOLINYL)OXY)ETHYL)-

Systematic Name

English

ETHANONE, 1-(4-(2-((4-((6-CHLORO-1,3-DIOXOLO(4,5-B)PYRIDIN-7-YL)AMINO)-5-(1-METHYLETHOXY)-7-QUINAZOLINYL)OXY)ETHYL)-1-PIPERAZINYL)-

Systematic Name

English

Code System Code Type Description

NCI_THESAURUS

C102976